Sharon Rozovsky is a Professor in the Department of Chemistry and Biochemistry at the University of Delaware's College of Arts & Sciences, where she leads research on oxidative stress response mechanisms and protein quality control pathways. Her work bridges biochemistry, chemical biology, and structural biology with direct implications for understanding neurodegenerative diseases and viral pathogenesis. Her academic foundation includes a B.S. from Tel Aviv University (1994) and a Ph.D. from Columbia University (2000), establishing her expertise in protein dynamics and redox biochemistry. These credentials underpin her innovative approaches to studying cellular stress responses. Rozovsky's research program centers on selenoproteins—proteins containing the rare amino acid selenocysteine—and their critical roles in endoplasmic reticulum (ER) stress resolution. She investigates how membrane-bound selenoproteins like Selenoprotein S and K regulate the ER-associated degradation (ERAD) pathway, with recent work revealing their surprising autoproteolytic activity and involvement in SARS-CoV-2 replication. Her lab pioneers chemical tools including expressed protein ligation and advanced 77Se NMR spectroscopy to characterize these systems at molecular resolution. Analysis of her 2021-2025 publications shows dominant themes in selenoprotein structure-function relationships, ER stress mechanisms, and viral interactions, alongside methodological innovations in cryo-EM grid technology and NMR. This body of work demonstrates consistent focus on redox biochemistry with expanding applications in virology and structural biology. No major scientific awards or fellowships were explicitly documented in the available materials, though her research impact is evident through high-impact publications and methodological contributions. She directs the active Rozovsky Research Group, mentoring graduate students and postdoctoral researchers in biochemical and biophysical techniques. Her laboratory operations are supported by competitive funding including an NSF CAREER award (2011) focused on selenoprotein reactivity, reflecting sustained recognition of her innovative research program.
Feng Feng is an Assistant Professor in the Department of Biochemistry and Molecular Biology at Oklahoma State University, where he has been employed since August 2020. His research focuses on understanding how plants interact with microbial communities in their rhizosphere under various environmental conditions. Dr. Feng received his Ph.D. in Plant Molecular Biology from Tsinghua University in Beijing, China (2008-2012), followed by an M.S. in Microbiology and B.S. in Biotechnology from Henan Agricultural University in Zhengzhou, China. Ph.D., Plant Molecular Biology, Tsinghua University, Beijing, China (2008-2012) M.S., Microbiology, Henan Agricultural University, Zhengzhou, China (2005-2008) B.S., Biotechnology, Henan Agricultural University, Zhengzhou, China (2001-2005) Dr. Feng's research interests center on plant-microbe interactions, particularly how plants balance immunity and symbiosis signaling pathways when encountering both pathogenic and beneficial microbes in the rhizosphere. His work examines how environmental conditions affect plant decisions to promote or inhibit microbial colonization, with the goal of developing cropping systems that require less chemical fertilizer and are more resilient to climate change. Using molecular, cell biology, genetic, and biochemical approaches, his lab investigates how abiotic environmental factors regulate plant-microbe interactions and how immunity and symbiosis signaling pathways influence broader microbial communities. Dr. Feng's scholarly output shows a consistent focus on plant immunity and symbiosis mechanisms, particularly involving LysM receptor-like kinases and their role in distinguishing between pathogenic and symbiotic microbial signals. His recent work has increasingly emphasized the ecological context of plant-microbe interactions and the potential applications for sustainable agriculture. Dr. Feng serves as an Associate Editor for Frontiers in Microbiology (since 2022) and has editorial roles with several other journals including Frontiers in Plant Science, Horticultural Plant Journal, and iMeta. Associate Editor, Frontiers in Microbiology (2022-present) Editorial Board, Frontiers in Plant Science (2021-present) Editorial Board, Horticultural Plant Journal (2021-present) Editorial Board, iMeta (2021-present) Dr. Feng actively mentors graduate students and postdoctoral researchers, with his lab currently recruiting Ph.D. students and postdocs interested in plant-microbe interactions. He has secured multiple research grants including funding from the U.S. Department of Agriculture and the Oklahoma Center for the Advancement of Science and Technology (OCAST). His laboratory investigates the molecular mechanisms by which plants regulate their interactions with rhizosphere communities, with particular focus on how environmental conditions influence the balance between immunity and symbiosis signaling pathways.
Anya L. Brown is an Assistant Professor in the Department of Evolution and Ecology at the University of California, Davis, based at the Bodega Marine Lab. Her research focuses on the community ecology of marine systems, particularly coral reefs, investigating how host-associated microbes and trait variation influence species resilience to stress, ecological interactions, and adaptive plasticity. Education: B.S. (Brown University, 2009), M.S. in Biology (California State University, Northridge, 2012), Ph.D. in Ecology (University of Georgia, 2018). Postdoctoral Experience: Ewel Postdoctoral Fellow in Tropical Ecology (University of Florida, 2018-2020); Postdoctoral Scholar in Marine Chemistry and Geochemistry (Woods Hole Oceanographic Institution, 2020-2022). Her recent publications highlight microbial dynamics in coral reefs, antibiotic effects on reef microbiomes, and trait-mediated interactions. She emphasizes interdisciplinary approaches, combining molecular tools with observational and experimental studies. The Brown Lab actively engages students in cross-system marine research, prioritizing inclusivity in scientific communities. Key trends in her work include understanding microbial responses to environmental stressors, coral disease mechanisms, and the role of extended phenotypes in reef ecology. These studies span tropical and temperate marine ecosystems, with implications for conservation and restoration. Scientific Awards: Hellman Fellowship 2024-25 Ewel Postdoctoral Fellowship in Tropical Ecology Dr. Brown's lab fosters research across coral reefs and local coastal systems, integrating ecological and microbial perspectives. She advocates for inclusive teaching and research practices while advancing microbial ecology frameworks in marine conservation.
Prof. Oliver Seitz leads the Bioorganic Synthesis research group at the Department of Chemistry, Faculty of Mathematics and Natural Sciences, Humboldt University of Berlin. His lab focuses on cutting-edge chemical biology approaches for protein/nucleic acid interrogation, with recent work advancing DNA/RNA-programmed assemblies for cellular imaging and therapeutic applications. Research spans chemical protein synthesis, glycoprotein/phosphoprotein engineering, and nucleic acid-templated reactions. Key innovations include Forced Intercalation (FIT) probes for wash-free RNA imaging, loss-of-affinity principles for catalytic efficiency, and peptide-PNA conjugates for targeted cellular delivery. The group actively develops tools for live-cell protein labeling and biomolecular spatial screening. Recent publications (2021-2024) emphasize fluorescence-based detection systems, catalytic templated reactions, and therapeutic peptide synthesis. Trends show increasing sophistication in multi-dye probes, glycan engineering, and RNA-triggered pro-drug activation. Scientific awards include: Max Bergmann Award (2019) Prof. Seitz actively advises doctoral students, with recent graduates Marvin Björn Stutz (2023, magna cum laude ), Dino Gluhacevic von Krüchten (2023, summa cum laude ), and Sophie Schöllkopf (2023, magna cum laude ). Current PhD candidates include Ekaterina Kazakova (glycoprotein synthesis), Alina Herfort (phosphoproteins), and Lina-Marie Beck (peptide-nucleic acid conjugates), with postdocs like Dr. Mandana Oloub (viscosity sensors). The Bioorganic Synthesis lab operates within Berlin's vibrant chemical research ecosystem, utilizing specialized techniques for chemical protein synthesis and nucleic acid detection. Recent team growth reflects ongoing projects in RNA imaging, catalytic templated reactions, and therapeutic conjugate development, supported by open positions for new researchers.
Professor Richard Wade-Martins is a leading academic in University of Oxford 's Department of Physiology, Anatomy and Genetics . He directs the Molecular Neurodegeneration Research Laboratory and the Oxford Parkinson’s Disease Centre (OPDC). With degrees from Cambridge (MA) and Oxford (DPhil), he has held prestigious fellowships including Wellcome Trust Research Career Development Fellowship and NIH reviewer roles. His research targets molecular mechanisms in Parkinson’s and Alzheimer’s diseases through iPSC models , transgenic mice , and lysosomal function studies . He pioneered work on SNCA , MAPT , and LRRK2 gene pathways. Current projects focus on gene therapy and mitochondrial dysfunction in neurodegeneration. Key publications (2019–2025) reveal trends in single-cell transcriptomics , calcium channel inhibition , and TFEB/TFE3 lysosome modulation . His awards include Wellcome Trust Fellowships and advisory roles for Parkinson's UK , Alzheimer's Research UK , and EU consortia like StemBANCC and EFACTS . He leads the UK Dementia Platform iPSC Initiative and serves on international boards in Luxembourg and Canada.
Professor Roland J. Pieters is a distinguished academic at Utrecht University's Faculty of Science, where he serves as a full Professor in the Department of Chemical Biology and Drug Discovery. With over two decades of experience at the institution, he has progressed from Assistant Professor (1998) to Associate Professor (2005) and ultimately to Full Professor (2010-present). His research group is internationally recognized for groundbreaking work at the intersection of carbohydrate chemistry, chemical biology, and drug discovery, with particular emphasis on developing novel therapeutic approaches against bacterial infections and pathogenic mechanisms. Full Professor, Utrecht University (2010-present) Associate Professor, Utrecht University (2005-2010) Assistant Professor, Utrecht University (1998-2005) NWO Talent Post-doctoral Fellow, ETH-Zürich (1995-1996) Postdoctoral Researcher, University of Groningen (1996-1998) Professor Pieters earned his M.Sc. in Organic Chemistry from the University of Groningen in 1990, where he worked with Professor Ben Feringa, and completed his Ph.D. at MIT in 1995 under the supervision of Professor Julius Rebek Jr. His doctoral research focused on molecular recognition and template effects in bisubstrate systems, establishing the foundation for his lifelong interest in molecular interactions. Professor Pieters' research primarily centers on glycodrugs and the strategic interference with protein-carbohydrate interactions using multivalent systems of varying architectures. His laboratory has made significant contributions to understanding how rigid spacers in multivalent ligands can dramatically enhance binding affinity to target proteins, with applications against viral and bacterial adhesion proteins, toxins, galectins, and glycosidases. A particular focus has been on developing inhibitors for Pseudomonas aeruginosa lectin LecA, cholera toxin, influenza virus hemagglutinin, and more recently, SARS-CoV-2 spike protein interactions with host cell receptors. His group also pioneered the use of glyco- and peptide-microarrays for high-throughput screening of carbohydrate-protein interactions and drug discovery, particularly in the area of O-GlcNAcylation research. The publication record of Professor Pieters demonstrates consistent innovation in the field of multivalent carbohydrate-based therapeutics. His recent work (2020-2024) shows a strategic expansion into viral pathogenesis (particularly influenza and SARS-CoV-2), immune modulation through glycan recognition, and novel approaches to vaccine development. A notable trend is the increasing sophistication of multivalent architectures, moving from simple divalent systems to tetra- and hexavalent ligands with precisely engineered spatial arrangements. His research bridges fundamental chemical principles with practical therapeutic applications, maintaining strong connections to pharmaceutical development while advancing basic science understanding of carbohydrate-mediated biological processes. Professor Pieters' scientific achievements have been recognized with prestigious awards including a Fellowship from the Royal Netherlands Academy of Arts and Sciences (KNAW) in 1999 and a VICI personal grant from the Netherlands Organisation for Scientific Research (NWO) in 2008. These competitive awards reflect the significance and innovation of his research program. He has also served on editorial advisory boards, notably as Section Editor-in-Chief for Chemical Biology in the journal Molecules (2018-2022), contributing to the scholarly community through peer review and academic leadership. Fellowship of Royal Netherlands Academy of Sciences (KNAW), 1999 VICI, personal grant, NWO, 2008 Section Editor-in-Chief Chemical Biology for Molecules (2018-2022) Throughout his career, Professor Pieters has coordinated significant research projects including the EU project POLYCARB and secured competitive funding that has sustained his innovative research program. His laboratory has fostered numerous collaborations across Europe and internationally, creating a vibrant research environment that has trained many scientists now working in academia and industry. His research on multivalent carbohydrate systems represents a sustained intellectual contribution to chemical biology with direct relevance to developing new anti-infective strategies and therapeutic approaches. Professor Pieters leads an active research group within Utrecht University's Department of Chemical Biology and Drug Discovery, situated in the David de Wied Building. His laboratory maintains strong connections with other research groups both within Utrecht University and internationally, particularly in the fields of glycobiology, infectious diseases, and drug discovery. The research environment he has cultivated emphasizes interdisciplinary approaches, combining synthetic chemistry, biophysical analysis, and biological testing to address fundamental questions in carbohydrate-mediated biological processes with therapeutic applications.
Antti Poso is a Professor of Drug Design at the University of Eastern Finland (Kuopio), affiliated with the School of Pharmacy under the Faculty of Health Sciences. His research focuses on computer-aided molecular design, particularly targeting anti-cancer drugs and anti-microbials. Key projects include the EDCMET project (2019–2024) and the GeneCellNano Flagship (2020–2028). He leads the Molecular Modeling and Drug Design Research Group, specializing in QSAR analysis, kinase inhibition profiling, and systems-level drug response modeling. Recent work includes studies on SARS-CoV-2 inhibitors, endocrine disruptors, and bacterial pathogenesis. His findings bridge chemical structure with biological outcomes, leveraging computational tools like CCA and molecular dynamics simulations. Collaborations span medicinal chemistry, pharmacology, and systems biology, contributing to both academic and applied drug discovery efforts. Education: Not explicitly stated in texts; assumed to hold advanced degrees in pharmacy or chemistry. Research Themes: Drug design, molecular modeling, QSAR, computational biology, and anti-infective agents. Key Contributions: Over 150+ publications, including influential works on chemoinformatics-driven drug response analysis and structure-based inhibitor design. Publications highlight advancements in kinase inhibitors, anti-microbial strategies, and viral hijacking mechanisms. His work emphasizes translating computational insights into therapeutic solutions for cancer, infectious diseases, and metabolic disorders.
Dr. Martin Anthony Fascione is a Reader in Chemistry at the University of York, where he leads the Fascione Lab within the Department of Chemistry. His research focuses on the interface between chemistry and biology, particularly in the field of chemical glycobiology. He has established himself as a leading researcher in carbohydrate chemistry with expertise in synthetic methods and biological applications. Dr. Fascione received his Ph.D. from the University of Leeds in 2009 under the supervision of W. Bruce Turnbull, followed by a Marie Curie International Outgoing Fellowship at the University of British Columbia with Prof. Steve Withers and the University of York with Prof. Gideon Davies. Since August 2014, he has been at the York Structural Biology Laboratory, progressing from Lecturer to his current position as Reader. His research centers on complex sugars (glycans) and their roles in biological processes and disease, with particular emphasis on sialic acid-like molecules critical for bacterial pathogens. The Fascione group develops chemical tools to study and perturb glycan activity in vivo using synthetic and enzymatic carbohydrate chemistry, organocatalysis, enzymology, and molecular biology. Key research areas include pseudaminic acid biosynthesis, protein bioconjugation, and glycoconjugate development for therapeutic applications. Analysis of Dr. Fascione's recent publications reveals a strong focus on bacterial glycans, particularly pseudaminic acid, and their role in pathogenesis. His work combines synthetic chemistry with biological applications, developing novel methods for protein modification, carbohydrate synthesis, and glycan-based therapeutics. Major themes include bioorthogonal chemistry, enzymatic synthesis of complex carbohydrates, and the development of glycoconjugates for therapeutic and diagnostic applications. Dr. Fascione has received significant recognition for his work, including: Marie Curie International Outgoing Fellowship (2012-2014) ERC Consolidator Grant (2022) As an active researcher, Dr. Fascione supervises PhD students and collaborates extensively with researchers in the UK and internationally. His laboratory is involved in multiple research projects focused on chemical glycobiology for infectious disease research and therapeutic development. The Fascione Lab has established itself as a leading center for research at the chemistry-biology interface, with particular expertise in carbohydrate-active enzymes and glycan-based tools for biological investigation.
Albert M. Berghuis is a Professor in the Department of Biochemistry at McGill University's Faculty of Medicine. His research focuses on structural mechanisms of antibiotic resistance and fungal pathogenesis using advanced techniques including X-ray crystallography, electron microscopy, and computational chemistry. His primary research interests include: Structural basis of antibiotic resistance mechanisms, particularly against aminoglycosides Development of novel antimicrobials through structure-based drug design Structural studies of fungal-specific metabolic pathways for antifungal drug discovery Enzyme mechanisms involving protein-small molecule interactions Analysis of his recent publications reveals a consistent focus on structural elucidation of resistance mechanisms, with particular emphasis on aminoglycoside-modifying enzymes and fungal targets. His work bridges structural biology with therapeutic development, showing strong translational potential in combating antimicrobial resistance. Professor Berghuis maintains the Berghuis Lab with facilities in both the McIntyre Medical Sciences Building and the Francesco Bellini Life Sciences Building. His laboratory employs integrated structural biology approaches to tackle pressing problems in infectious disease treatment.
Hans Steenackers is an Associate Professor at the Faculty of Bioscience Engineering, KU Leuven, where he leads the MICA Lab within the Department of Microbial and Molecular Systems. His research focuses on innovative antimicrobial strategies targeting microbial communities, including socio-active, anti-resistance, and observation-guided approaches. Key research areas include biofilm dynamics antimicrobial resistance evolution in situ microbial monitoring Salmonella Typhimurium pathogenesis anti-virulence therapies His recent publications highlight advancements in biofilm inhibition, triggered antimicrobial release systems, and evolutionary robustness of probiotics. The majority of his work involves interdisciplinary collaborations, particularly in projects like TARDIS, ULTiMatE-MS, and MICROTUNe, with a focus on translating fundamental research into clinical applications. As an educator, he teaches advanced courses in microbial physiology, biofilm research, and applied biotechnology. The MICA Lab actively partners with academic and industrial stakeholders in initiatives such as the Flemish Scientific Research Network on Biofilms and the Bioclean H2020 project.
Julie M. Goddard is a Professor of Food Science at Cornell University , affiliated with the College of Agriculture and Life Sciences and the Department of Food Science . Her research focuses on Biomaterials and Biointerfaces , with emphasis on food quality, safety, and sustainability. She leads the Goddard Research Group, which develops innovative polymeric materials and coatings for food packaging, bioprocessing, and equipment. Key projects include antimicrobial/nonfouling coatings, biocatalytic materials, and active packaging to reduce synthetic additives and food waste. Dr. Goddard holds a Bachelor of Science (1999) and Ph.D. (2008) in Food Science from Cornell University. Her work is supported by grants from USDA NIFA, NIH, NSF, and FFAR. Notable awards include the National Excellence in Multistate Research Award (2019) , APLU Junior Moulton Medal (2015) , and Institute of Food Technologists Young Scientist Award (2013) . Her research spans nonmigratory active packaging (e.g., antioxidant, antimicrobial films), biofilm inhibition , and enzyme immobilization . Recent articles highlight advancements in PETase engineering for microplastic degradation and optimization of curcumin-grafted biodegradable materials. She collaborates across disciplines, including materials science, chemical engineering, and microbiology. Labs/Teams: The Goddard Group operates in Stocking Hall, Cornell. Projects include biocatalytic packaging , hydrogen sulfide formation in canned beverages , and consumer acceptance of novel food technologies . Key grants fund exploration of bio-based materials and food safety innovations.
Prof Jean Van Den Elsen is a Professor of Biochemistry at the University of Bath , affiliated with the Department of Life Sciences and several research centers including the Centre for Sustainable Chemical Technologies (CSCT) , Centre for Therapeutic Innovation , and Milner Centre for Evolution . They are actively accepting doctoral students and leading multidisciplinary projects at the intersection of structural biology and immunology. Education: Not explicitly mentioned Appointments: University of Bath (current), with collaborations across Chemistry, Biology & Biochemistry departments Research Focus: The laboratory investigates protein structural biology in two major areas: Complement System Interactions: Studying how pathogenic microbes like Staphylococcus aureus evade host immunity through complement system manipulation , with structural analysis of proteins such as C3d and C5 complexes. This work directly informs vaccine design and autoimmune disease treatment . Glycation Mechanisms: Developing diagnostic tools for detecting non-enzymatic sugar modifications linked to diabetes , Alzheimer's , and aging, with commercial partnerships like Abcam . Article Trends: Recent publications demonstrate: Structural analysis of complement evasion proteins (2022-2025) Engineering knob domains as miniature antibodies (2023) Evolutionary studies on cooperative behavior (2021-2025) Advancements in peptide synthesis platforms (2022-2023) Applications of AI protein folding (2020) Scientific Contributions: ORCID: 0000-0002-0367-1956 BBSRC Funding recipient (2023) 100+ citations across 76 research outputs Student Mentorship: Directly supervising 4 current PhD students and 1 postdoc, with a track record of mentoring 11 previous students including Daphne Jackson Fellows and MSCA researchers. Collaborations: Maintains active partnerships with Dr. Tony James (Chemistry), Dr. Rob Williams (Biochemistry), and industry partners UCB Celltech and Porton Biopharma Ltd. Their work contributes to UN Sustainable Development Goals 3 (Good Health), 12 (Responsible Consumption), and 13 (Climate Action).
Kyu Y. Rhee is a Professor of Medicine and Professor of Microbiology and Immunology at Weill Cornell Medical College . His research focuses on Mycobacterium tuberculosis , with emphasis on metabolic pathways , antibiotic resistance mechanisms , and drug development . Research highlights include: Multi-omic approaches to TB drug discovery Mechanistic studies of antibiotic action Deciphering TB transmission genetics Metabolomics-driven target identification Current funding includes: Bill & Melinda Gates Foundation : AI/ML-assisted bacterial permeability platform National Institute of Allergy & Infectious Diseases : UM1 TB drug regimen design consortium National Heart, Lung, & Blood Institute : Studies on M. tuberculosis PE/PPE proteins and fructose-induced cancer He has authored over 50 publications on TB metabolomics, drug development, and pathogen persistence. His work bridges systems biology , chemical biology , and clinical research to address antimicrobial resistance.
Anne Berit C. Samuelsen serves as Associate Professor at the Department of Pharmacy, University of Oslo, where she also holds the position of Head of Education. Her academic foundation includes a Cand.pharm. degree and Dr.scient. doctorate, establishing her expertise in pharmaceutical sciences. Her research centers on polysaccharides from natural sources—particularly higher plants, cereals, and fungi (Basidiomycota)—with specialized focus on β-glucans. Key interests include carbohydrate chemistry, pharmacognosy, and the development of biopolymer-based pharmaceutical applications. Her work bridges fundamental structural characterization with practical drug delivery solutions, notably through liposome coating technologies and immunomodulatory compound development. Recent publications reveal a strong trajectory in fungal polysaccharide research, particularly with Pleurotus eryngii and Albatrellus ovinus species. Her team employs advanced techniques like diffusion-ordered NMR spectroscopy to analyze polysaccharide structures while investigating biological activities related to immune receptor binding (Dectin-1, Toll-like receptors) and therapeutic applications. This work demonstrates consistent output in high-impact journals including Carbohydrate Polymers and ACS Applied Bio Materials . She actively contributes to academic instruction through courses such as FARM1150 (Pharmaceutically Oriented Biochemistry), FARM3100 (Pharmacognosy), and FARM5200 (Use of Biopolymers in Pharmaceuticals). Her leadership extends to the Bioactive Natural Substances and Health Effects (BioNatH) research group and the Glyconor Consortium, where she investigates natural product applications for health improvement.
Dr. Richard Y. Zhao is a tenured Professor in the Department of Pathology and Microbiology-Immunology at the University of Maryland School of Medicine. His research combines molecular biology, fission yeast genetics, mammalian biology, and virology to study virus-host interactions, particularly for HIV and Zika virus. He previously held academic positions at Northwestern University and Columbia University and has contributed to over 120 peer-reviewed articles. B.S., China Oceanography University (1981) M.S., Oregon State University (1995) Ph.D., Oregon State University (1991) Postdoctoral Training, Columbia University (1991-1992) Dr. Zhao's research focuses on: Virus-host interactions and pathogenicity High-throughput drug screening for antivirals Role of viral proteins in neuroinflammation and cancer Translational genomics in precision medicine His recent publications highlight SARS-CoV-2 ORF3a, Zika envelope proteins, and HIV protease inhibitors, emphasizing host-pathogen mechanisms across species. He has served on NIH panels and editorial boards for journals like Cell Research and Retrovirology . Scientific awards include: Fellow, American Academy of Microbiology (2019) Bernard L Mirkin Endowed Chair (2001-2004) Honorary Director, Shandong Gallo Institute (2009) Distinguished Service from SCBA (2015) Outstanding Service from CBA-USA (2016) Dr. Zhao also contributes to clinical diagnostics and personalized medicine through molecular testing and pharmacogenetics programs.
